Skip to main content
Clinical Trials/JPRN-UMIN000013261
JPRN-UMIN000013261CompletedPhase 2

A Phase II study of Neoadjuvant chemotherapy in Docetaxel and Cyclophosphamide(TC therapy) with Operable HER2 Negative breast cancer - A Phase II study of Neoadjuvant chemotherapy in Docetaxel and Cyclophosphamide(TC therapy) with Operable HER2 Negative breast cancer

Kyoto Prefectural University of Medicine0 sites50 target enrollmentStarted: February 28, 2014Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 70years-old (—)
Sex
Female

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1)Poorly controlled complication (malignant hypertension, myocardial infarction , congestive heart failure, bleeding). 2)Multiple primary cancer 3)Synchronous bilateral breast cancer 4)Interstitial pneumonia and pulmonary fibrosis diagnosed by chest X-rays or CT scan. 5)Women who are pregnant, lactating or with childbearing potential 6)Hypersensitivity to any agents necessary in the planned treatment. 7)Serious peripheral neuropathy or serious edema 8)Pleural effusion or cardiac effusion which requires treatment 9)Complication which requires prior treatment with corticosteroid 10)Suspected infection 11)Ineligible based on decision of an investigator

Investigators

Similar Trials